thalidomide has been researched along with Heart Failure in 25 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide has recently shown to improve LVEF in chronic heart failure patients, accompanied by a marked decrease in plasma levels of tumor necrosis factor alpha (TNF-alpha)." | 9.12 | Effects of thalidomide treatment in heart failure patients. ( Arrieta-Rodríguez, O; Asensio-Lafuente, E; Castillo-Martínez, L; Dorantes-García, J; Granados-Arriola, J; Orea-Tejeda, A; Rodríguez-Reyna, T, 2007) |
| "Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD)." | 9.11 | Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. ( Andreassen, A; Aukrust, P; Breivik, K; Fjeld, JG; Frøland, SS; Følling, M; Gullestad, L; Gundersen, T; Hodt, A; Holt, E; Kjekshus, E; Kjekshus, J; Semb, AG; Skårdal, R; Ueland, T; Wergeland, R; Yndestad, A, 2005) |
| "Thalidomide was assessed in preclinical and clinical studies." | 6.70 | Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. ( Agoston, I; Bozkurt, B; Dibbs, ZI; Mann, DL; Muller, G; Wang, F; Zeldis, JB, 2002) |
| "NYHA cardiac failure staging was the only independent factor affecting overall survival." | 5.43 | Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. ( Avivi, I; Ballan-Haj, M; Chubar, E; Cohen, Y; Dally, N; Gatt, ME; Hardan, I; Jakubinsky, J; Magen, H; Muchtar, E; Patachenco, P; Shevetz, O; Suriu, C; Tadmor, T; Trestman, S; Yeganeh, S, 2016) |
| " Thalidomide has recently shown to improve LVEF in chronic heart failure patients, accompanied by a marked decrease in plasma levels of tumor necrosis factor alpha (TNF-alpha)." | 5.12 | Effects of thalidomide treatment in heart failure patients. ( Arrieta-Rodríguez, O; Asensio-Lafuente, E; Castillo-Martínez, L; Dorantes-García, J; Granados-Arriola, J; Orea-Tejeda, A; Rodríguez-Reyna, T, 2007) |
| "Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD)." | 5.11 | Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. ( Andreassen, A; Aukrust, P; Breivik, K; Fjeld, JG; Frøland, SS; Følling, M; Gullestad, L; Gundersen, T; Hodt, A; Holt, E; Kjekshus, E; Kjekshus, J; Semb, AG; Skårdal, R; Ueland, T; Wergeland, R; Yndestad, A, 2005) |
| "Thalidomide was assessed in preclinical and clinical studies." | 2.70 | Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. ( Agoston, I; Bozkurt, B; Dibbs, ZI; Mann, DL; Muller, G; Wang, F; Zeldis, JB, 2002) |
| "Thalidomide is an anti-angiogenic compound that may offer a potential option for management of refractory LVAD-related GIB." | 1.46 | Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients. ( Chan, LL; Kerk, KL; Lim, CP; Seng, BJJ; Sim, DKL; Sivathasan, C; Soon, JL; Tan, TE; Teo, LLY, 2017) |
| "NYHA cardiac failure staging was the only independent factor affecting overall survival." | 1.43 | Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. ( Avivi, I; Ballan-Haj, M; Chubar, E; Cohen, Y; Dally, N; Gatt, ME; Hardan, I; Jakubinsky, J; Magen, H; Muchtar, E; Patachenco, P; Shevetz, O; Suriu, C; Tadmor, T; Trestman, S; Yeganeh, S, 2016) |
| "Echocardiography detected left ventricular hypertrophy and diastolic dysfunction." | 1.39 | Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. ( Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 13 (52.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Namdaran, P | 1 |
| Zikos, TA | 1 |
| Pan, JY | 1 |
| Banerjee, D | 2 |
| Seng, BJJ | 1 |
| Teo, LLY | 1 |
| Chan, LL | 1 |
| Sim, DKL | 1 |
| Kerk, KL | 1 |
| Soon, JL | 1 |
| Tan, TE | 1 |
| Sivathasan, C | 1 |
| Lim, CP | 1 |
| Imamura, T | 1 |
| Kinugawa, K | 1 |
| Uriel, N | 1 |
| Arnall, JR | 1 |
| Usmani, SZ | 1 |
| Adamu, H | 1 |
| Mishkin, J | 1 |
| Bhutani, M | 1 |
| Tokuyama, M | 1 |
| Shimizu, T | 1 |
| Yamada, T | 1 |
| Kondoh, A | 1 |
| Mabuchi, T | 1 |
| Yokokawa, T | 1 |
| Nakazato, K | 1 |
| Kanno, Y | 1 |
| Mizukami, H | 1 |
| Kobayashi, A | 1 |
| Yoshihisa, A | 1 |
| Takahashi, H | 1 |
| Shichishima-Nakamura, A | 1 |
| Ohkawara, H | 1 |
| Noji, H | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Ogawa, K | 1 |
| Hisa, S | 1 |
| Takeishi, Y | 1 |
| Draper, K | 1 |
| Kale, P | 1 |
| Martin, B | 1 |
| Kelly Cordero, R | 1 |
| Ha, R | 1 |
| Mann, DL | 3 |
| Gatt, ME | 1 |
| Hardan, I | 1 |
| Chubar, E | 1 |
| Suriu, C | 1 |
| Tadmor, T | 1 |
| Shevetz, O | 1 |
| Patachenco, P | 1 |
| Dally, N | 1 |
| Yeganeh, S | 1 |
| Ballan-Haj, M | 1 |
| Cohen, Y | 1 |
| Trestman, S | 1 |
| Muchtar, E | 1 |
| Magen, H | 1 |
| Jakubinsky, J | 1 |
| Avivi, I | 1 |
| Palladini, G | 1 |
| Russo, P | 1 |
| Lavatelli, F | 1 |
| Nuvolone, M | 1 |
| Albertini, R | 1 |
| Bosoni, T | 1 |
| Perfetti, V | 1 |
| Obici, L | 1 |
| Perlini, S | 1 |
| Moratti, R | 1 |
| Merlini, G | 1 |
| Blum, A | 1 |
| Inoue, D | 1 |
| Kato, A | 1 |
| Tabata, S | 1 |
| Kitai, T | 1 |
| Takiuchi, Y | 1 |
| Kimura, T | 1 |
| Shimoji, S | 1 |
| Mori, M | 1 |
| Nagai, Y | 1 |
| Togami, K | 1 |
| Matsushita, A | 1 |
| Nagai, K | 1 |
| Maruoka, H | 1 |
| Imai, Y | 1 |
| Beppu, M | 1 |
| Kawamoto, M | 1 |
| Takahashi, T | 1 |
| Tageja, N | 1 |
| Dispenzieri, A | 1 |
| Dingli, D | 1 |
| Kumar, SK | 1 |
| Rajkumar, SV | 1 |
| Lacy, MQ | 1 |
| Hayman, S | 1 |
| Buadi, F | 1 |
| Zeldenrust, S | 1 |
| Leung, N | 1 |
| Detweiler-Short, K | 1 |
| Lust, JA | 1 |
| Russell, SJ | 1 |
| Kyle, RA | 1 |
| Gertz, MA | 1 |
| Falk, RH | 1 |
| Gadó, K | 1 |
| Domján, G | 1 |
| Vescovo, G | 1 |
| Ravara, B | 1 |
| Angelini, A | 1 |
| Sandri, M | 1 |
| Carraro, U | 1 |
| Ceconi, C | 1 |
| Dalla Libera, L | 1 |
| Agoston, I | 1 |
| Dibbs, ZI | 1 |
| Wang, F | 1 |
| Muller, G | 1 |
| Zeldis, JB | 1 |
| Bozkurt, B | 1 |
| Gullestad, L | 3 |
| Semb, AG | 2 |
| Holt, E | 2 |
| Skårdal, R | 2 |
| Ueland, T | 3 |
| Yndestad, A | 3 |
| Frøland, SS | 2 |
| Aukrust, P | 3 |
| Fjeld, JG | 1 |
| Gundersen, T | 1 |
| Breivik, K | 1 |
| Følling, M | 1 |
| Hodt, A | 1 |
| Kjekshus, J | 1 |
| Andreassen, A | 1 |
| Kjekshus, E | 1 |
| Wergeland, R | 1 |
| Damås, JK | 1 |
| Orea-Tejeda, A | 1 |
| Arrieta-Rodríguez, O | 1 |
| Castillo-Martínez, L | 1 |
| Rodríguez-Reyna, T | 1 |
| Asensio-Lafuente, E | 1 |
| Granados-Arriola, J | 1 |
| Dorantes-García, J | 1 |
| McGowan, N | 1 |
| Davey, PP | 1 |
| Ashrafian, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis.[NCT01510613] | Phase 2 | 28 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| GutHeart: Targeting Gut Microbiota to Treat Heart Failure[NCT02637167] | Phase 2 | 150 participants (Anticipated) | Interventional | 2016-03-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for thalidomide and Heart Failure
| Article | Year |
|---|---|
Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device.
Topics: Anticoagulants; Blood Component Transfusion; Fish Oils; Gastrointestinal Hemorrhage; Heart Failure; | 2018 |
Innate immunity and the failing heart: the cytokine hypothesis revisited.
Topics: Adaptive Immunity; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Autoantibodies; Autoim | 2015 |
Immunological mediated therapies for heart failure.
Topics: Heart Failure; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosorbents; Immunosupp | 2009 |
[AL amyloidosis].
Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Inflammatory mediators and the failing heart: past, present, and the foreseeable future.
Topics: Animals; Antibodies, Monoclonal; Antirheumatic Agents; Clinical Trials as Topic; Cytokines; Disease | 2002 |
Anti-inflammatory trials in chronic heart failure.
Topics: Adult; Aged; Animals; Cytokines; Female; Free Radical Scavengers; Heart Failure; Humans; Immunoglobu | 2006 |
What's wrong with this patient? Primary systemic amyloidosis.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Diagnosis, Differential; Disease Progres | 2006 |
New therapies for heart failure: is thalidomide the answer?
Topics: Heart Failure; Humans; Immunosuppressive Agents; Thalidomide; Tumor Necrosis Factor-alpha | 2000 |
4 trials available for thalidomide and Heart Failure
| Article | Year |
|---|---|
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
Topics: Aged; Amyloidosis; Dexamethasone; Drug Therapy, Combination; Female; Heart Diseases; Heart Failure; | 2009 |
Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure.
Topics: Adult; Aged; Blood Pressure; Cytokines; Dose-Response Relationship, Drug; Drug Evaluation; Female; H | 2002 |
Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study.
Topics: Aged; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow | 2005 |
Effects of thalidomide treatment in heart failure patients.
Topics: Aged; Biomarkers; Cardiovascular Agents; Female; Heart Failure; Humans; Male; Middle Aged; Prospecti | 2007 |
13 other studies available for thalidomide and Heart Failure
| Article | Year |
|---|---|
Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices.
Topics: Adult; Aged; Arteriovenous Malformations; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart- | 2020 |
Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart-Assi | 2017 |
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Dexamethasone; Female; Heart Failure; Hematopoietic | 2019 |
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment.
Topics: Aged; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Creatinine; Electrocardiography; | 2019 |
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome.
Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertens | 2013 |
Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol.
Topics: Adult; Aged; Angiodysplasia; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Gast | 2015 |
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Topics: Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bortezomi | 2016 |
Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy; Drug Therapy, Combination; Female; Heart Fail | 2010 |
POEMS syndrome, congestive heart failure and thalidomide -food for thought.
Topics: Capillary Leak Syndrome; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Inflammati | 2010 |
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Topics: Amyloid; Amyloidosis; Biomarkers; Clinical Trials as Topic; Combined Modality Therapy; Cyclophospham | 2010 |
Cardiac amyloidosis: a treatable disease, often overlooked.
Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2011 |
Effect of thalidomide on the skeletal muscle in experimental heart failure.
Topics: Animals; Apoptosis; Heart Failure; Monocrotaline; Muscle, Skeletal; Muscular Atrophy; Myosin Heavy C | 2002 |
Effect of thalidomide in patients with chronic heart failure.
Topics: Aged; Biomarkers; Female; Heart Failure; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; | 2002 |